The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
DiaMedica said it plans to launch the trial later in 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The company announced positive topline data from the Phase II ZUPREME-1 trial
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
Subscribe To Our Newsletter & Stay Updated
